Conclusion: Manifestations of sarcoidosis vary significantly across the paediatric age spectrum. While EOS is a known juvenile idiopathic arthritis mimic, lymphadenitis and GIT inflammation may lead to a non-rheumatologic malignancy. Apart from specific infections other childhood diseases may also present with granuloma formation. Crohn’s disease, chronic granulomatous disease and other primary immunodeficiencies, granulomatosis with polyangiitis. Our small series reflects disease heterogeneity and diagnostic difficulties that prolonged the diagnosis by years in 4/7 patients.

References

Disclosure of Interests: None declared


AB0966

PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEERODERMA RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018

Ivan Foeldvari1, Kathryn Torok2, Lusine Ambartsumyan7, Jordi Anton3, Christian Blakely4, Tamas Constantini5, Patricia Costa Reis6, Megan Curran2, Maurizio Cutolo2, Francesco De Galdio2, Christopher Denton2, Kim Fligelstone2, Bernhard Hinerichi2, Antonia Höger2, Francesca Ingegnoli2, Ozgur Kasacopuur2, Liz Suzannen2, Dana Nemcova2, Catherine Orteu5, Clarissa Pilkington6, Vanessa Smith4, Brandi Stevens2, Allison Zheng2, Dinesh Khanna2, Daniel Furst1, 1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany; 2Participant of the Hamburg Outcome measure consensus process, Hamburg, Germany

Background: Juvenile systemic sclerosis (JSSc) is an orphan disease, associated with high morbidity and mortality. New treatment strategies are much needed. To develop an open label drug trial for the treatment of JSSc patients, it is necessary to clearly define how to evaluate outcomes in this disease, which are currently not existing. A group of experts in JSSc has met annually and worked to index an evaluate to outcomes in this disease.

Objectives: The aim of our third consensus meeting was to establish the domains and the items that should be assessed in a clinical trial in JSSc.

Methods: In the consensus meeting 26 JSSc international experts with various specialties participated (22 voted). In a nominal group technique, moderated by DEF, was used to develop the outcome measures. Agreement was defined if 80% or more of the participants approved an item.

Results: Domains and items suggested in the 2017 consensus meeting were reconsidered and selected or rejected during the 2018 meeting, as were additional domains/items (Table).

Domain | Item | voted for - yes/nominator
--- | --- | ---
Global Disease Activity | Physician global of disease activity 22/22 | Change in HAQ/DAS- DI 22/22 | Scleroderma HAQ 22/22
Skin | Change in Modified Rodnan Skin Score 22/22 | Raynaud Phenomenon | Scleroderma HAQ question regarding Raynaud
Digital ulcerations | Scleroderma HAQ question regarding Raynaud 22/22 | Raynaud
Newborn Schafer | Juvenile idiopathic arthritis definition of active joint 22/22 | Cardiac Involvement | Left ventricular ejection fraction 22/22 | Development of clinically significant arrhythmia as a sign of non-response
Pulmonary Involvement | FVC 22/22 | age-defined DLCO in all trials 20/20 | Pulmonary Involvement
Renal | New occurrence of renal crisis 22/22 | Gastrointestinal Involvement | Body Mass Index 22/22 | Scleroderma HAQ-Gastrointestinal section 22/22
Global health/Health related Quality of Life (QOL) | QOL instrument should be used 18/18

Conclusion: We reached consensus on domains and items which should be assessed in an open label 1 year clinical JSSc trial. We also listed research items which should be assessed but should not currently be included as an outcome in such a trial.

Disclosure of Interests: Ivan Foeldvari Consultant for: Chugui, Novartis, Kathryin Torok: None declared, Lusine Ambartsumyan: None declared, Jordi Anton Grant/research support from: Grant/research support, consultant or speakers bureau from AbbVie, Alexion, Bristol-Myers Squibb, Chemocentrix, Gebro, GlaxoSmithKline, Novartis, Novimmune, Pfizer, Roche, Sanofi and Sobi, Consultant for: Grant/research support, consultant or speakers bureau from AbbVie, Alexion, Bristol-Myers Squibb, Chemocentrix, Gebro, GlaxoSmithKline, Novartis, Novimmune, Pfizer, Roche, Sanofi and Sobi, Speakers bureau: Grant/research support, consultant or speakers bureau from AbbVie, Alexion, Bristol-Myers Squibb, Chemocentrix, Gebro, GlaxoSmithKline, Novartis, Novimmune, Pfizer, Roche, Sanofi and Sobi, Christian Beyer: None declared, Michael Blakely: None declared, Tamas Constantini: None declared, Patricia Costa Reis: None declared, Megan Curran: None declared, Maurizio Cutolo: None declared, Francesco Del Galdio: None declared, Christopher Denton Grant/research support from: GlaxoSmithKline, Inventiva, CSF Behring, Consultant for: Roche, Genentech, Actelion, GlaxoSmithKline, Sanofi, Aventis, Inventiva, CSL Behring, Boehringer Ingelheim, Bayer, Kim Fligelstone: None declared, Bernd Hinrichs: None declared, Antonia Höger: None declared, Francesca Ingegnoli: None declared, Ozgur Kasacopuur: None declared, Suzanne Li: None declared, Dana Nemcova: None declared, Catherine Orteu: None declared, Clarissa Pilkington: None declared, Vanessa Smith: None declared, Brandi Stevens: None declared, Allison Zheng: None declared, Dinesh Khanna: Daniel Furst1, 1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany; 2Participant of the Hamburg Outcome measure consensus process, Hamburg, Germany

REFERENCES

Disclosure of Interests: None declared


AB0967

IS THERE A DIFFERENCE IN PRESENTATION OF FEMALE AND MALE PATIENTS WITH JUVENILE SYSTEMIC SCLERODERMA. AN UPDATE FROM THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM

Ivan Foeldvari1, Jens Klotzsche2, Ozgur Kasacopuur2, Amra Adrovic3, Kathryn Torok4, Valley Stanevich4, Rivka S. Szajnbok5, Ana Paula Sakamoto5, Ekaterina Alexeeva6, Jordi Anton7, Maria Katsikas7, Vanessa Smith4, Tadej Avcin3, Anjali Patwardhan3, Yosef Uziel3, Nicola Helmus1, Dragana Lazarevic3, Kirsten Minden2, Susan Nielsen3, Farzana Nuruzzaman3, Lillemor Berntson3, Blanca Bica3, Juergen Brunner3, Patricia Costa Reis3, Rolando Cimaz3, Mikhail Kostik3, Thomas Lehman3, Walter Alberto Sifuentes-Giraldo4, Simone Appenizzer1, Mahesh Janarthanan7, Monika Moll5, Dana Nemcova2, Maria Jose Santos8, Amarissa Battaglotti9, Lillemor Bernstorn10, Bianca Bics10, Juergen Brunner10, Patricia Costa Reis5, Despina Elefteriou11, Lora Harel12, Gerard Horvath13, Tilman Kallinich13, Dragana Lazarevic14, Kirsten Minder1, Susan Nielsen1, Farzana Nuruzzaman1, Anjali Patwardhan1, Yosef Uziel1, Nicola Helmus1, 1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany; 2Deutsches Rheuma Forschungszentrum (DRFZ), Berlin, Germany; 3jSSc Collaborative Group, Hamburg, Germany

Background: Juvenile systemic scleroderma (JSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children (1). There are limited data published regarding the differences in clinical presentation of male and female patients with JSSc. The Juvenile Systemic Scleroderma Inception Cohort (JSSIC) is a multinational cohort with a prospective standardized assessment of the patients. The data regarding the difference in clinical characteristics at time of inclusion in the cohort are presented.

Objectives: Evaluation of the differences in clinical presentation of male and female patients with JSSc, who fulfill the adult classification criteria (2), and presented the first non-Raynaud symptoms before 16 years old and were younger than 18 years old at the time of inclusion in the cohort. Patients with a previous diagnosis of JSSc were also included as an outcome in such a trial.

Methods: The JSSIC is a prospective multicentre registry of patients with JSSc, who fulfill the adult classification criteria (2), and presented the first non-Raynaud symptoms before 16 years old and were younger than 18 years old at the time of inclusion in the cohort. Patients with a previous diagnosis of JSSc were also included as an outcome in such a trial.

Results: As of 15th of December 2018 120 patients are included in JSSIC. The great majority are female (80%). There were more female patients with CK elevation (29% vs 22%) and more female patients with Gottron papulae (25% vs 12%). The mean modified skin score was higher in males (18.6 vs 13.9).

Sclerodactyly was more frequent in males (90% vs 76%). Active ulceration was present in 33% of males compared to 14% of females (p=0.026). FVC 80% occurred more often in males with 47% compared to 24% in females (p=0.018). Pulmonary hypertension was more